The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Try the newly designed Company Pages!
Switch now

Teva Pharmaceutical

  • TEVA
  • NYSE
  • Consumer Products
  • Latest 53.21
  • Currency US$
  • Change -0.05
  • Percent Change -0.094 %
  • Volume 3,597,287
  • Wed Oct 22, 2014 04:02 PM EDT NYSE data delayed 15 minutes.
  • Open 52.99
  • Previous Close 53.26
  • High 54.05
  • Low 52.88
  • Bidx20 53.38
  • Askx18 53.52
  • 52-week High07/24 55.70
  • 52-week Low11/05 36.26
  • Beta 0.756
  • Market Cap 50,382.95M
  • EPS 5.14
  • P/E 10.352
  • Forward P/E 10.90
  • PEG 1.03
  • Annual Dividend 1.37
  • Yield 2.575

News

Financials & Calendars

Income Statement

  • Sales $20,414,000,000
  • Earnings $1,383,000,000
  • Return on Equity 6.06%

Cash Flow

  • Cash Flow --
  • Cash $901,000,000
  • Current Ratio 1.18

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $46,892,000,000
  • Liabilities $23,862,000,000
  • Liabilities-to-Equity Ratio 1.04

Price Ratios

  • Price to Sales 2.47
  • Price to Book 2.19
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Jul 31 $1.22 Oct 30 $1.21
Surprises Jul 31 0.82% n/a n/a
Dividends Aug 19 $0.34 n/a n/a
Splits n/a -- n/a n/a

12 months ended Oct 23, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.

Related Securities
Symbol Type Latest % Chg

Officers

  • Dr. Phillip Frost Chairman
  • Erez Vigodman President and Chief Executive
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

5 Basel Street P.O. Box 3190
PETACH TIKVA, L3
49131

Phone: (972)-3926-7267

kevin.mannix@tevapharm.com
www.tevapharm.com

Ideas & Discussion

Live Discussion of TEVA on StockTwits
The Globe and Mail has
updated our Company Pages
Switch to the newly designed Company Pages format today for a more in-depth look at the companies you're following and pages that are easier to navigate. If you prefer the old layout after trying the new Company Pages, you can switch back anytime.